Question of the Day

Question of the Day – Monday July 3, 2017

Question: The reference cited below notesOver the past decade, artemisinin-based combination therapies (ACTs) have been deployed as first- and second- line treatments for uncomplicated malaria across malaria-endemic regions. Since 2001, this deployment has included the delivery of over 500 million treatments of artemether-lumefantrine (AL), making it one of the most widely prescribed drugs worldwide”. What neurologic toxicity is of most concern in patients receiving ACTs?

View full post for answer.